Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | PLK1 | P53350 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | HTR6 | P50406 | 8/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.47 |
| ▸ | TNF | P01375 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6765084 | 0.85 | LMNA (0.71) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL6769055 | 0.85 | LMNA (0.71) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL946621 | 0.85 | LMNA (0.71) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL30393652 | 0.84 | LMNA (1.00) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL949716 | 0.84 | LMNA (1.00) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL6765180 | 0.81 | LMNA (0.65) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL28791772 | 0.79 | HTR6 (0.48) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL6768288 | 0.79 | LMNA (0.59) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL12344906 | 0.78 | HTR6 (0.64) | LMNASMN1; SMN2PLK1MEN1KMT2A | |
| SCHEMBL30394720 | 0.78 | LMNA (0.68) | LMNASMN1; SMN2PLK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | EXELIXIS, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| EP-2320895-A2 | CDK MODULATORS | Exelixis, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010003133-A2 | CDK MODULATORS | EXELIXIS INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201599-A1 | CDK Modulators | CDK3, CDK1, CDKL1 | LMNA 2517/4885SMN1; SMN2 1814/4885PLK1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.